Outbreak of meropenem-resistant Serratia marcescens comediated by chromosomal AmpC β-lactamase overproduction and outer membrane protein loss

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 12, 2010, Pages 5057-5061

  Suh, Borum ^a   Bae, Il Kwon ^a   Kim, Juwon ^a   Jeong, Seok Hoon ^a   Yong, Dongeun ^a   Lee, Kyungwon ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

AZTREONAM; BETA LACTAMASE AMPC; BETA LACTAMASE CTX M; BETA LACTAMASE CTX M22; BORONIC ACID DERIVATIVE; CARBAPENEMASE; CEFOTAXIME; CEFOXITIN; CEFTAZIDIME; CIPROFLOXACIN; CLAVULANIC ACID; CLOXACILLIN; GENTAMICIN; IMIPENEM; MEROPENEM; OUTER MEMBRANE PROTEIN F; PIPERACILLIN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC SENSITIVITY; ANTIFUNGAL RESISTANCE; ARTICLE; CLINICAL ARTICLE; FEMALE; GENE EXPRESSION; GENE SEQUENCE; HUMAN; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SERRATIA MARCESCENS;

ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; BACTERIAL OUTER MEMBRANE PROTEINS; BACTERIAL PROTEINS; BETA-LACTAMASES; BLOTTING, SOUTHERN; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MOLECULAR SEQUENCE DATA; POLYMERASE CHAIN REACTION; PORINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SERRATIA INFECTIONS; SERRATIA MARCESCENS; THIENAMYCINS; YOUNG ADULT;

EID: 78649654934     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00768-10     Document Type: Article

References (25)

1. Bradford, P. A., C. Urban, N. Mariano, S. J. Projan, J. J. Rahal, and K. Bush. 1997. Imipenem resistance in Klebsiella pneumoniae is associated with the combination of ACT-1, a plasmid-mediated AmpC β-lactamase, and the foss of an outer membrane protein. Antimicrob. Agents Chemother. 41:563-569.
2. Carlone, G. M., M. L. Thomas, H. S. Rumschlag, and F. O. Sottnek. 1986. Rapid microprocedure for isolating detergent-insoluble outer membrane proteins from Haemophilus species. J. Clin. Microbiol. 24:330-332.
3. Clinical and Laboratory Standards Institute. 2006. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A8, 8th ed. CLSI, Wayne, PA.
4. Clinical and Laboratory Standards Institute. 2009. Performance standards for antimicrobial susceptibility testing. Nineteenth informational supplement. M100-S19. CLSI, Wayne, PA.
5. Deshpande, L. M., R. N. Jones, T. R. Fritsche, and H. S. Sader. 2006. Occurrence and characterization of carbapenemase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program (2000-2004). Microb. Drug Resist. 12:223-230.
6. Hanson, N. D., and C. C. Sanders. 1999. Regulation of inducible AmpC β-lactamase expression among Enterobacteriaceae. Curr. Pharm. Des. 5:881-894.
7. Hernandez-Alles, S., V. J. Benedi, L. Martinez-Martinez, A. Pascual, A. Aguilar, J. M. Tomas, and S. Alberti. 1999. Development of resistance during antimicrobial therapy caused by insertion sequence interruption of porin genes. Antimicrob. Agents Chemother. 43:937-939.
8. Hidri, N., G. Barnaud, D. Decre, C. Cerceau, V. Lalande, J. C. Petit, R. Labia, and G. Arlet. 2005. Resistance to ceftazidime is associated with a S220Y substitution in the omega loop of the AmpC β-lactamase of a Serratia marcescens clinical isolate. J. Antimicrob. Chemother. 55:496-499.
9. Ivanova, D., R. Markovska, N. Hadjieva, I. Schneider, I. Mitov, and A. Bauernfeind. 2008. Extended-spectrum β-lactamase-producing Serratia marcescens outbreak in a Bulgarian hospital. J. Hosp. Infect. 70:60-65.
10. Jacoby, G. A. 2009. AmpC β-lactamases. Clin. Microbiol. Rev. 22:161-182.
11. Jeong, S. H., W. Song, M. J. Park, J. S. Kim, H. S. Kim, I. K. Bae, and K. M. Lee. 2008. Boronic acid disk tests for identification of extended-spectrum β-lactamase production in clinical isolates of Enterobacteriaceae producing chromosomal AmpC β-lactamases. Int. J. Antimicrob. Agents 31:467-471.
12. Lee, C. H., C. Chu, J. W. Liu, Y. S. Chen, C. J. Chiu, and L. H. Su. 2007. Collateral damage of flomoxef therapy: in vivo development of porin deficiency and acquisition of blaDHA-1 leading to ertapenem resistance in a clinical isolate of Klebsiella pneumoniae producing CTX-M-3 and SHV-5 β-lactamases. J. Antimicrob. Chemother. 60:410-413.
13. Lee, H. K., Y. J. Park, J. Y. Kim, E. Chang, S. G. Cho, H. S. Chae, and C. S. Kang. 2005. Prevalence of decreased susceptibility to carbapenems among Serratia marcescens, Enterobacter cloacae, and Citrobacter freundii and investigation of carbapenemases. Diagn. Microbiol. Infect. Dis. 52:331-336.
14. Lee, K., Y. Chong, H. B. Shin, Y. A. Kim, D. Yong, and J. H. Yum. 2001. Modified Hodge and EDTA-disk synergy tests to screen metallo-β-lactamase- producing strains of Pseudomonas and Acinetobacter species. Clin. Microbiol. Infect. 7:88-91.
15. Lee, K., Y. S. Lim, D. Yong, J. H. Yum, and Y. Chong. 2003. Evaluation of the Hodge test and the imipenem-EDTA double-disk synergy test for differentiating metallo-β-lactamase-producing isolates of Pseudomonas spp. and Acinetobacter spp. J. Clin. Microbiol. 41:4623-4629. (Pubitemid 37259767)
16. Mammeri, H., L. Poirel, P. Bemer, H. Drugeon, and P. Nordmann. 2004. Resistance to cefepime and cefpirome due to a 4-amino-acid deletion in the chromosome-encoded AmpC β-lactamase of a Serratia marcescens clinical isolate. Antimicrob. Agents Chemother. 48:716-720.
17. Matsumura, N., S. Minami, and S. Mitsuhashi. 1998. Sequences of homologous β-lactamases from clinical isolates of Serratia marcescens with different substrate specificities. Antimicrob. Agents Chemother. 42:176-179.
18. Nomura, K., and T. Yoshida. 1990. Nucleotide sequence of the Serratia marcescens SR50 chromosomal ampC β-lactamase gene. FEMS Microbiol. Lett. 58:295-299.
19. Osano, E., Y. Arakawa, R. Wacharotayankun, M. Ohta, T. Horii, H. Ito, F. Yoshimura, and N. Kato. 1994. Molecular characterization of an enterobacterial metallo-β-lactamase found in a clinical isolate of Serratia marcescens that shows imipenem resistance. Antimicrob. Agents Chemother. 38:71-78.
20. Queenan, A. M., C. Torres-Viera, H. S. Gold, Y. Carmeli, G. M. Eliopoulos, R. C. Moellering, Jr., J. P. Quinn, J. Hindler, A. A. Medeiros, and K. Bush. 2000. SME-type carbapenem-hydrolyzing class A β-lactamases from geographically diverse Serratia marcescens strains. Antimicrob. Agents Chemother. 44:3035-3039.
21. Song, W., H. Lee, K. Lee, S. H. Jeong, I. K. Bae, J. S. Kim, and H. S. Kwak. 2009. CTX-M-14 and CTX-M-15 enzymes are the dominant type of extended-spectrum β-lactamase in clinical isolates of Escherichia coli from Korea. J. Med. Microbiol. 58:261-266.
22. Yang, Y. J., P. J. Wu, and D. M. Livermore. 1990. Biochemical characterization of a β-lactamase that hydrolyzes penems and carbapenems from two Serratia marcescens isolates. Antimicrob. Agents Chemother. 34:755-758.
23. Yatsuyanagi, J., S. Saito, T. Konno, S. Harata, N. Suzuki, J. Kato, and K. Amano. 2006. Nosocomial outbreak of ceftazidime-resistant Serratia marcescens strains that produce a chromosomal AmpC variant with N235K substitution. Jpn. J. Infect. Dis. 59:153-159.
24. Yum, J. H., D. Yong, K. Lee, H. S. Kim, and Y. Chong. 2002. A new integron carrying VIM-2 metallo-β-lactamase gene cassette in a Serratia marcescens isolate. Diagn. Microbiol. Infect. Dis. 42:217-219.
25. Zhang, R., H. W. Zhou, J. C. Cai, and G. X. Chen. 2007. Plasmid-mediated carbapenem-hydrolysing β-lactamase KPC-2 in carbapenem-resistant Serratia marcescens isolates from Hangzhou, China. J. Antimicrob. Chemother. 59:574-576.